Search results for "Lymphocyte Subsets"

showing 10 items of 212 documents

Phenotypical and Functional Alteration of γδ T Lymphocytes in COVID-19 Patients: Reversal by Statins

2022

(1) Background: statins have been considered an attractive class of drugs in the pharmacological setting of COVID-19 due to their pleiotropic properties and their use correlates with decreased mortality in hospitalized COVID-19 patients. Furthermore, it is well known that statins, which block the mevalonate pathway, affect γδ T lymphocyte activation. As γδ T cells participate in the inflammatory process of COVID-19, we have investigated the therapeutical potential of statins as a tool to inhibit γδ T cell pro-inflammatory activities; (2) Methods: we harvested peripheral blood mononuclear cells (PBMCs) from COVID-19 patients with mild clinical manifestatio…

T-Lymphocyte SubsetsSARS-CoV-2 infectionLeukocytes Mononuclearmevalonate pathwaystatinHumansCOVID-19γδ T cells; COVID-19; SARS-CoV-2 infection; statin; mevalonate pathwayReceptors Antigen T-Cell gamma-deltaGeneral MedicineHydroxymethylglutaryl-CoA Reductase Inhibitorsγδ T cellsCOVID-19 Drug TreatmentCells; Volume 11; Issue 21; Pages: 3449
researchProduct

Editorial: Activation, functions, and generation of immunological memory in γδ T lymphocytes: lessons from nonhuman primates

2014

T cells constitute an unconventional lymphocyte population with distinct functions complementary to those of CD4 and CD8 T cells. As such, they have both adaptive features, such as expression of the TCR, and innate-like functions reminiscent of NK cells, with whom they share extensive repertoires of activating and inhibitory receptors [1, 2]. Although most antigens recognized by murine T cells remain obscure, advances have been made in identifying ligands for human T cells. The majority of circulating human T lymphocytes expresses a TCR formed by the preferentially-paired V 9 and V 2 chains (here and thereafter, called V 9V 2 T cells). Instead of binding peptides associated with molecules b…

TRAIL.T cellLymphocyteImmunologyPopulationMajor histocompatibility complexAntigenT-Lymphocyte SubsetsmedicineAnimalsImmunology and AllergyCytotoxic T cellListeriosiseducationLungAntigens Bacterialeducation.field_of_studyTumorbiologyEffectorT-cell receptorCell Biologygamma delta cellListeria monocytogenesOrganophosphatesCell biologymedicine.anatomical_structureBacterial VaccinesImmunologybiology.proteinSpotlight on Leading Edge ResearchImmunizationImmunologic MemoryJournal of Leukocyte Biology
researchProduct

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

1997

Abstract The current study was carried out to elucidate the immunoregulatory changes induced by venom immunotherapy (VIT) in bee or wasp allergic subjects. All subjects included in this study had a history of severe systemic allergic reactions to stings of the respective insect as well as positive skin tests with the respective venom or venom-specific IgE in the sera. Parameters assessed in peripheral blood mononuclear cells (PBMC) before and after initiation of VIT (rush therapy reaching a maintenance dose of 100 micrograms venom injected subcutaneously within 1 week) were expression of CD3, CD4, CD8, CD45RA, CD45RO, interleukin (IL)-2 receptor (R) alpha, IL-4R, IL-12R, Fc epsilon RII, CD4…

Time Factorsmedicine.medical_treatmentImmunologyCD40 LigandDown-RegulationVenomWasp VenomsImmunoglobulin ELigandsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaTh2 CellsAntigens CDT-Lymphocyte SubsetsmedicineImmunology and AllergyHumansLymphocyte CountRNA MessengerCD40 AntigensCD40Membrane GlycoproteinsbiologyReceptors IgEInterleukinAntibodies MonoclonalInsect Bites and StingsReceptors InterleukinAllergensTh1 CellsInterleukin-10Receptors Interleukin-4Interleukin 10Bee VenomsCytokineDesensitization ImmunologicImmunologyAntigens Surfacebiology.proteinInterleukin-4AntibodyEuropean journal of immunology
researchProduct

Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells.

2011

We have identified a novel interleukin (IL)-7-responsive T cell population [forkhead box P3 (FoxP3(+) ) CD4(+) CD25(+) CD127(+) ] that is comparably functionally suppressive to conventional FoxP3(+) CD4(+) CD25(+) regulatory T cells (T(regs) ). Although IL-2 is the most critical cytokine for thymic development of FoxP3(+) T(regs) , in the periphery other cytokines can be compensatory. CD25(+) CD127(+) T cells treated with IL-7 phenotypically 'matured' into the known 'classical' FoxP3(+) CD4(+) CD25(high) CD127(-) FoxP3(+) T(regs) . In freshly isolated splenocytes, the highest level of FoxP3 expression was found in CD127(+) CD25(+) T cells when compared with CD127(-) CD25(+) or CD127(+) CD25…

Translational StudiesT cellImmunologyActive Transport Cell Nucleuschemical and pharmacologic phenomenaBiologyT-Lymphocytes RegulatoryInterleukin-7 Receptor alpha SubunitInterleukin 21MiceAntigenAntigens CDT-Lymphocyte SubsetsmedicineImmunology and AllergyCytotoxic T cellAnimalsCTLA-4 AntigenIL-2 receptorInterleukin-7 receptorCells CulturedCell NucleusMice Inbred BALB CInterleukin-7autoimmunityInterleukin-2 Receptor alpha SubunitFOXP3virus diseaseshemic and immune systemsCell DifferentiationForkhead Transcription FactorsT lymphocyteMice Inbred C57BLmedicine.anatomical_structureGene Expression RegulationImmunologyLeukocyte Common AntigensFoxP3 TregClinical and experimental immunology
researchProduct

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease…

2003

CD8(+) T cells play a central role in immune protection against infection with Mycobacterium tuberculosis. One of the target epitopes for anti-M. tuberculosis directed CD8(+) T cells is the HLA-A2-restricted 19-kDa lipoprotein peptide VLTDGNPPEV. T cell clones directed against this epitope recognized not only the nominal peptide ligand, but also a closely related peptide (VPTDPNPPEV) from the HIV envelope gp120 (HIV(env) gp120) protein characterized by IFN-gamma release. This cross-reactivity was confirmed in ex vivo in M. tuberculosis 19-kDa tetramer-sorted T cells from patients with tuberculosis and in HIVgp120 tetramer-reactive T cells sorted from HIV(+) patients. M. tuberculosis 19-kDa …

TuberculosisHIV AntigensT cellImmunologyEpitopes T-LymphocyteHIV InfectionsCD146 AntigenBiologyCD8-Positive T-LymphocytesCross ReactionsHIV Envelope Protein gp120medicine.disease_causeEpitopeMycobacterium tuberculosisInterferon-gammaViral ProteinsAntigenBacterial ProteinsAntigens CDT-Lymphocyte SubsetsHLA-A2 AntigenmedicineImmunology and AllergyHumansTuberculosisLongitudinal StudiesNeural Cell Adhesion MoleculesAntigens BacterialMembrane GlycoproteinsMolecular MimicryGranulocyte-Macrophage Colony-Stimulating FactorT lymphocyteMycobacterium tuberculosisOncogene Proteins Viralmedicine.diseasebiology.organism_classificationVirologyPeptide FragmentsDNA-Binding ProteinsMolecular mimicrymedicine.anatomical_structureImmunologyInterleukin-4CD8BiomarkersEuropean journal of immunology
researchProduct

Biology of gama delta T Cells in Tuberculosis and Malaria

2002

Tuberculosis and malaria remain the leading causes of mortality among human infectious diseases in the world. It is estimated that 3 to 5 million people die from tuberculosis and malaria each year. Although it is traditionally believed that CD4 and CD8 alphabeta T lymphocytes are mandatory for protective immune responses against Mycobacterium tuberculosis and Plasmodium falciparum (the ethiologic agents of tuberculosis and the most severe form of malaria, respectively), there is still incomplete understanding of the mechanisms of immune protection and of the causes of its failure in the affected patients. Several studies in humans and animal models have suggested that Vgamma9/Vdelta2 T cell…

TuberculosisT cellPlasmodium falciparumBiochemistryMycobacterium tuberculosisMiceImmune systemAntigenT-Lymphocyte Subsetsparasitic diseasesmedicineAnimalsHumansTuberculosisMalaria FalciparumMolecular BiologybiologyReceptors Antigen T-Cell gamma-deltaPlasmodium falciparumMycobacterium tuberculosisGeneral Medicinemedicine.diseasebiology.organism_classificationVirologyDisease Models Animalmedicine.anatomical_structureImmunologyMolecular MedicineCD8MalariaCurrent Molecular Medicine
researchProduct

Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes

2019

γδ T lymphocytes represent ∼1% of human peripheral blood mononuclear cells and even more cells in most tissues of vertebrates. Although they have important anticancer functions, most current single-cell RNA sequencing (scRNA-seq) studies do not identify γδ T lymphocytes because their transcriptomes at the single-cell level are unknown. Here we show that high-resolution clustering of large scRNA-seq datasets and a combination of gene signatures allow the specific detection of human γδ T lymphocytes and identification of their T cell receptor (TCR)Vδ1 and TCRVδ2 subsets in large datasets from complex cell mixtures. In t -distributed stochastic neighbor embedding plots from blood and tumor sa…

[SDV.BIO]Life Sciences [q-bio]/BiotechnologyLymphocyte[SDV]Life Sciences [q-bio]CD8-Positive T-Lymphocytes[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityTranscriptome0302 clinical medicineT-Lymphocyte Subsets[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Cytotoxic T cellsingle-cell RNA-sequencingCells CulturedT-lymphocytesComputingMilieux_MISCELLANEOUSCancer0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMultidisciplinarygamma delta T lymphocyteReceptors Antigen T-Cell gamma-deltaCell biologyKiller Cells Naturalmedicine.anatomical_structurePNAS Plus030220 oncology & carcinogenesis[SDV.IMM]Life Sciences [q-bio]/Immunologyγδ T lymphocyteexpression des gènesAdultT cellBiologylymphocytePeripheral blood mononuclear cell03 medical and health sciencesAntigenséquençage arnr 16smedicineHumansCell Proliferation030304 developmental biologyhuman immunologyBase SequenceSequence Analysis RNAT-cell receptor[SDV.BIO] Life Sciences [q-bio]/BiotechnologyLeukocytes MononuclearImmunologic MemorytranscriptomeCD8[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct

Immunotherapy targeting colon cancer stem cells

2010

In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinical studies have recently demonstrated that adding immune therapy to chemotherapy has survival benefits in comparison with chemotherapy alone that can sensitize tumors to immune cell-mediated killing (e.g., increasing sensitivity of tumor cells to subsequent cytotoxicity by T cells via upregulation of death receptors DR5 and Fas). However, loss of MHC molecules is often observe…

cancer stem cellsAdoptive cell transferT-LymphocytesT cellImmunologyBiologyCell therapyNK-92T-Lymphocyte SubsetsCancer stem cellmedicinegamma delta T cellsHumansImmunology and AllergyNK cellSettore MED/04 - Patologia Generalecolon cancer stem cellschemoresistanceReceptors Antigen T-Cell gamma-deltaSuicide geneKiller Cells Naturalmedicine.anatomical_structureOncologyColonic NeoplasmsImmunologyCancer cellNeoplastic Stem CellsImmunotherapygamma delta T cells cancer stem cells chemoresistance immunotherapy NK cellStem cellImmunotherapy
researchProduct